Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Director/PDMR Shareholding

12 Dec 2006 18:33

ReGen Therapeutics PLC12 December 2006 Notification of Change in Interests of Directors London: On 12 December 2006 options ("Options") were granted to directors of theCompany in respect of an aggregate of 43,200,000 ordinary shares of 0.1p each inthe Company ("Ordinary Shares"). The Options, taken with existing options andwarrants over Ordinary Shares, will, if exercised, represent 5.77 per cent ofthe then enlarged issued share capital of the Company. All Options were granted with an exercise price of 1.25p per Ordinary Share (theclosing mid-market price on 12 December 2006) and may normally be exercisedbetween 31 December 2007 and 12 December 2016. The exercise of all Options issubject to first meeting performance conditions based on product launch andachieving certain revenue and profit targets over 2007, 2008 and 2009. Prior toreceiving these grants the executive Directors cancelled all previously grantedoptions (which were not subject to performance targets). No amounts were paid for the grants themselves. Percy Lomax was granted 13,000,000 Options. Following this announcement Mr Lomaxholds a total of 2,282,069 Ordinary Shares (representing 0.33 per cent of issuedshare capital) and 13,000,000 options over Ordinary Shares in the capital of theCompany. Timothy Shilton was granted 9,000,000 Options. Following this announcement MrShilton holds a total of 500,000 Ordinary Shares (representing 0.07 per cent ofissued share capital) and 9,000,000 options over Ordinary Shares in the capitalof the Company. Norman Lott was granted 8,000,000 Options. Following this announcement Mr Lottholds a total of 182,000 Ordinary Shares (representing 0.026 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Martin Small was granted 8,000,000 Options. Following this announcement Mr Smallholds a total of 2,248,736 Ordinary Shares (representing 0.32 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Keith Corbin was granted 2,700,000 Options. Following this announcement MrCorbin holds a total of 1,105,000 Ordinary Shares (representing 0.16 per cent ofissued share capital) and 3,300,000 options over Ordinary Shares in the capitalof the Company. Peter Garrod was granted 2,500,000 Options. Following this announcement MrGarrod holds a total of 66,750,000 Ordinary Shares (representing 9.61 per centof issued share capital) and 2,500,000 options over Ordinary Shares in thecapital of the Company. Further Information Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jun 202011:00 amRNSPrice Monitoring Extension
29th Jun 20209:05 amRNSSecond Price Monitoring Extn
29th Jun 20209:00 amRNSPrice Monitoring Extension
29th Jun 20207:00 amRNSAgreement with STC Biologics
23rd Jun 202012:20 pmRNSNotice of AGM
22nd Jun 20207:00 amRNSExercise of Warrants and Issue of Equity
19th Jun 20209:05 amRNSSecond Price Monitoring Extn
19th Jun 20209:00 amRNSPrice Monitoring Extension
19th Jun 20207:00 amRNSPatent Granted for Oral Administration
18th Jun 20205:30 pmRNSDirectorate Change
18th Jun 20207:00 amRNSFinal Results
12th Jun 20207:00 amRNSExtension of At the Market Sales Agreement
4th Jun 20207:00 amRNSAnti-CD3 for Alzheimer Disease
2nd Jun 20204:03 pmRNSCorrection Issue of Equity and Total Voting Rights
2nd Jun 20207:00 amRNSIssue of Equity and Total Voting Rights
1st Jun 20207:00 amRNSChange of Adviser
29th May 20207:00 amRNSFurther re: ASCO Conference - StemPrintER
26th May 20204:42 pmRNSSecond Price Monitoring Extn
26th May 20204:37 pmRNSPrice Monitoring Extension
22nd May 20209:05 amRNSSecond Price Monitoring Extn
22nd May 20209:00 amRNSPrice Monitoring Extension
22nd May 20207:00 amRNSIntention to Demerge StemPrintER
21st May 20204:05 pmRNSHolding(s) in Company
18th May 20202:39 pmRNSExercise of Warrants and Issue of Equity
18th May 202011:05 amRNSSecond Price Monitoring Extn
18th May 202011:00 amRNSPrice Monitoring Extension
14th May 20203:00 pmRNSASCO Conference - Milciclib
14th May 20202:06 pmRNSSecond Price Monitoring Extn
14th May 20202:00 pmRNSPrice Monitoring Extension
14th May 202011:05 amRNSSecond Price Monitoring Extn
14th May 202011:00 amRNSPrice Monitoring Extension
14th May 20209:05 amRNSSecond Price Monitoring Extn
14th May 20209:00 amRNSPrice Monitoring Extension
14th May 20207:00 amRNSASCO Conference - StemPrintER
13th May 202011:06 amRNSSecond Price Monitoring Extn
13th May 202011:00 amRNSPrice Monitoring Extension
11th May 202010:47 amRNSHolding(s) in Company
11th May 20207:00 amRNSASCO Conference
7th May 202011:06 amRNSSecond Price Monitoring Extn
7th May 202011:00 amRNSPrice Monitoring Extension
6th May 202012:13 pmRNSResult of GM
6th May 20207:00 amRNSHolding(s) in Company
1st May 20207:00 amRNSTotal Voting Rights
28th Apr 20202:00 pmRNSPrice Monitoring Extension
28th Apr 202011:05 amRNSSecond Price Monitoring Extn
28th Apr 202011:00 amRNSPrice Monitoring Extension
27th Apr 20202:01 pmRNSPrice Monitoring Extension
27th Apr 20201:30 pmRNSPatent Application Filing
24th Apr 20206:29 pmRNSAcquisition of Technology
24th Apr 20207:00 amRNSIssue of Equity and Update on AIM Cancellation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.